Drug Type Gene therapy |
Synonyms Epodure, Erythropoietin gene therapy, MDGN 201 TARGTepo secreting EPO + [2] |
Target |
Mechanism EPO receptor modulators(Erythropoietin receptor modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Phase 2 | US | 01 Jun 2015 | |
Parkinson Disease | Phase 2 | US | 01 Jun 2015 | |
Anemia of renal disease | Phase 2 | IL | 01 Apr 2015 | |
Anemia of renal disease | Phase 2 | IL | 01 Apr 2015 | |
Kidney Failure, Chronic | Phase 2 | IL | 01 Apr 2015 | |
Kidney Failure, Chronic | Phase 2 | IL | 01 Apr 2015 |
Phase 2 | 2 | (Group A) | tbwskphpqo(pkaasnrsmu) = hnllmcyhlz vtfuaewdfn (wrzfjylbin, neqvgdbnms - egcrrqwnid) View more | - | 19 Oct 2018 | ||
(Group B) | tbwskphpqo(pkaasnrsmu) = vqbjgroijc vtfuaewdfn (wrzfjylbin, uignaydbhl - bxgoeodedj) View more | ||||||
Phase 1/2 | 7 | EPODURE Biopump 20 IU/kg/day | wkznydruar(atvreaxcdv) = kaxlcubwqe qujzvsaxfi (ovinlrnhod ) | Positive | 16 Nov 2010 | ||
EPODURE Biopump 40 IU/kg/day | wkznydruar(atvreaxcdv) = zvhnmybwom qujzvsaxfi (ovinlrnhod ) | ||||||
Phase 1/2 | 7 | EPODURE low dose (20 IU/kg/day) | wjxkwolxry(lwhnagbrrf) = ngwdfmnefy pbvofbbwyy (qakkpphfce ) | Positive | 01 May 2010 | ||
EPODURE high dose (40 IU/kg/day) | wjxkwolxry(lwhnagbrrf) = pwmhwqyboc pbvofbbwyy (qakkpphfce ) |